Consolidated revenue increased by 34% yoy to Rs331.3cr in the quarter under review, as against Rs247.2cr a year ago same period. However, Q1 review was marginally down by 1.2% from Rs335.4cr of Q4FY20.
EBITDA was Rs70.2cr in Q1FY21 compared to Rs34.6cr in Q1 FY20, representing a rise of 102.9%. While EBITDA Margin stood at 21.2% for Q1 FY21 as against 14.0% in Q1 FY20.
Mark Saldanha, Managing Director of the Company said “I am happy to state that we have achieved another quarter of robust performance, wherein we achieved our highest ever EBITDA of Rs70.2cr. This was due to all-round growth across geographies. I wish to place on record my gratitude to our employees who have tirelessly worked despite the operational challenges faced from the
pandemic. We remain cautiously confident of delivering such superior performance going forward.”
Marksans' other business highlights during Q1 as per the filing are:
- Company achieved revenue of Rs144.2cr. from Europe, UK: Formulation business in Q1FY21 as compared to Rs100.9cr.achieved during last year same period registering a growth of 43.0%
- US & North America Formulation business reported growth of 29.0% to Rs 133.6cr. in QFY21
- Australia & NZ Formulation business revenue was at Rs34.1cr. in QIFY21, registering a growth of 10.8% YoY
- Rest of World Formulation business was Rs19.4cr. in Q1FY21
On Sensex, Marksans Pharma stock was trading at the upper circuit limit of Rs43.65 per piece, up by 4.93% at around 2.26 pm.